In clinical practice, wet AMD patients are currently treated with intravitreal anti-VEGF agents including Lucentis (Ranibizumab), Eylea (Aflibercept) and bevacizumab (avastin)13, 14. The gene discussed is VEGFA; the disease is wet macular degeneration.